DNA

Business Context and Reporting Period

Company: Ginkgo Bioworks Holdings, Inc. (NYSE: DNA)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2025
Business Overview: Ginkgo operates two primary segments: Cell Engineering, providing biological R&D services via its Foundry and Codebase platform, and Biosecurity, offering biomonitoring and bioinformatics services (Canopy and Horizon) to government and commercial clients. The company is currently executing a restructuring plan initiated in Q2 2024 to reduce operational expenditures, including a workforce reduction of over 50% and facility consolidations.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased by $10.4 million (27.3%) year-over-year. Cell Engineering revenue rose to $38.2 million from $27.9 million, while Biosecurity revenue remained flat at $10.1 million.
• Expense Reduction: Operating expenses decreased significantly by $78.7 million. Research and Development (R&D) expenses dropped $65.5 million to $70.9 million, and General and Administrative (G&A) expenses fell $21.2 million to $49.0 million, driven by the restructuring plan and reduced stock-based compensation.
• Restructuring Charges: The company incurred $5.3 million in restructuring charges in Q1 2025, primarily for employee termination benefits, compared to none in Q1 2024.
• Investment Activity: The company began investing excess cash in marketable debt securities in Q1 2025, purchasing $191.2 million of securities, resulting in a net cash outflow from investing activities of $198.7 million.
• Non-Cash Revenue Impact: A significant portion of the revenue increase ($7.5 million) was non-cash, resulting from the release of deferred revenue following the termination of a contract with BiomEdit, Inc.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management states that cash and marketable securities of $516.9 million are sufficient to fund operations for at least the next 12 months. Expenditures are expected to exceed revenue through this period.
• Restructuring Progress: Workforce reductions are expected to be substantially completed in 2025. Facility consolidation is ongoing, with timing for subleasing excess space dependent on market conditions. Future restructuring charges related to asset impairments or lease terminations could be material.
• Commercial Strategy: The company continues to shift commercial terms, removing downstream value share from certain new program types and launching new "cell engineering tools" offerings (Datapoints and lab automation) to generate shorter-duration revenue.
• Risks: Key risks include the ability to raise additional capital, intense competition, reliance on customers to commercialize engineered products, and the volatility of equity investments in customers. The company also faces risks related to the successful execution of its restructuring and facility subleasing.

Investor Verification Checklist

• Non-Cash Revenue Quality: Verify the sustainability of revenue growth given that $7.5 million of the Q1 increase was a one-time release of deferred revenue from a terminated contract (BiomEdit).
• Cash Burn Rate: Monitor the net cash used in operating activities ($51.5 million in Q1) against the $516.9 million liquidity position to assess runway duration.
• Restructuring Costs: Track future quarters for additional restructuring charges related to facility consolidations and asset impairments, which management notes could be material.
• Investment Valuation: Review the fair value of notes receivable and equity investments, which are subject to significant volatility and impairment risks (e.g., $1.8 million impairment loss recorded in Q1).
• Stock-Based Compensation: Note the significant reduction in stock-based compensation ($20.4M vs $40.8M YoY) and assess if this trend is sustainable or if future grants (including new performance-based RSUs) will increase expenses.